BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-01-24
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 750
- Registration Number
- NCT00102141
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-01-11
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 52
- Registration Number
- NCT00101413
BAY43-9006 - Phase II in Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-01-11
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT00101400
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-12-16
- Last Posted Date
- 2008-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2244
- Registration Number
- NCT00099502
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Bayer
- Registration Number
- NCT00086775
- Locations
- πΊπΈ
Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States
πΊπΈHillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
πΊπΈJackson Oncology Associates, PLLC, Jackson, Mississippi, United States
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 501
- Registration Number
- NCT00079612
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 903
- Registration Number
- NCT00073307
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 56
- Registration Number
- NCT00059462
Repinotan in Patients With Acute Ischemic Stroke
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-09-09
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 782
- Registration Number
- NCT00044915
Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT00044538
Β© Copyright 2024. All Rights Reserved by MedPath